CLAIMS

1. A synergistic combination comprising at least one Sigma ligand and at least one Non-steroidal Anti-inflammatory Drug (NSAID), wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt or solvate thereof, and wherein the NSAID is selected from the group consisting of paracetamol, ibuprofen, naproxen, diclofenac, celecoxib and metamizole.

2. The synergistic combination according to claim 1, wherein the combination comprises:

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a salt thereof and diclofenac or celecoxib; or

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a salt thereof and metamizole; or

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a salt thereof and ibuprofen or naproxen; or

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a salt thereof and paracetamol.

3. The synergistic combination according to any one of the preceding claims, wherein the combination comprises:

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and diclofenac or celecoxib; or

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and metamizole; or

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and ibuprofen or naproxen; or

4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and paracetamol.

4. The synergistic combination according to any one of the preceding claims for use in the prophylaxis and/or treatment of pain.

5. The synergistic combination for use according to claim 4 wherein the pain is selected from peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis and neuropathy.

6. The synergistic combination for use according to claim 4 wherein the pain is post-operative pain.

7. Use of a sigma ligand as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for synergistically potentiating the analgesic effect of an NSAID when said NSAID is used in the prophylaxis and/or treatment of pain.